跳至主要内容
临床试验/NCT04442958
NCT04442958已完成不适用

Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome

Bagcilar Training and Research Hospital2 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2020年5月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
2
主要终点
Plasma fibrinogen level

研究概览

简要总结

The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.

详细描述

The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of Covid-19

排除标准

  • Age lower than 18 Lower plasma IgA levels PaO2/FiO2 higher than 300 mmHg SpO2 higher than 90

结局指标

主要结局

Plasma fibrinogen level

时间窗: 7. day

Coagulopathy

Plasma procalcitonin level

时间窗: 7. day

Infection markers

Plasma ferritin level

时间窗: 7. day

Acute phase reactant

D-Dimer level

时间窗: 7. day

Hypercoagulability

C-Reactive protein level

时间窗: 7. day

Infection markers

Lymphocyte count

时间窗: 7. day

Infection markers

次要结局

  • Fractional Inspired Oxygen Level(7. day)
  • Partial Oxygen Saturation level(7. day)
  • Arterial Oxygen level(7. day)

研究者

发起方
Bagcilar Training and Research Hospital
申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验